<DOC>
	<DOC>NCT00252915</DOC>
	<brief_summary>There is basic science evidence that GM-CSF reconstructs cellular immunity in septic patients. In this prospective, randomised double-blind, placebo-controlled trial, we investigate whether this can be achieved in patients with severe sepsis and septic shock.</brief_summary>
	<brief_title>Reconstruction of Monocytic Immunocompetence by Granulocyte-macrophage-colony Stimulating Factor (GM-CSF) in Patients With Severe Sepsis and Septic Shock</brief_title>
	<detailed_description>GM-CSF reconstructs cellular immunity in septic patients. In this prospective, randomised double-blind, placebo-controlled trial, we investigate whether this can be achieved in patinets with severe sepsis and septic shock.</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Shock, Septic</mesh_term>
	<criteria>Severe sepsis or septic shock, Presence of infection, 2 SIRS criteria, Acute organ dysfunction, Immunoparalysis, Informed consent Pregnancy, Known allergies to study medication or components, Moribound patient, Autoimmune disease, HIVinfection, Acute MI or pulmonary embolism, Cpr during last 72 hours, Patients who participate in a different clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>